Comparing translations of the EORTC QLQ-C30 using differential item functioning analyses-Reference-Cited by-同舟云学术

Comparing translations of the EORTC QLQ-C30 using differential item functioning analyses

Published:2006-08 Issue:6 Volume:15 Page:1103-1115
ISSN:0962-9343
Container-title:Quality of Life Research
language:en
Short-container-title:Qual Life Res

Author:

Scott N. W., ,Fayers P. M.,Bottomley A.,Aaronson N. K.,de Graeff A,Groenvold M.,Koller M.,Petersen M. A.,Sprangers M. A. G.

Publisher

Springer Science and Business Media LLC

Subject

Public Health, Environmental and Occupational Health

Link

http://link.springer.com/content/pdf/10.1007/s11136-006-0040-x.pdf

Reference33 articles.

1. The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology

2. Aaronson NK, Cull AM, Kaasa S, Sprangers MAG. The European Organization for Research and Treatment of Cancer EORTC) modular approach to quality of life assessment in oncology: an update. In: Spilker B (ed.), Quality of Life and Pharmacoeconomics in Clinical Trials, 2nd ed. Lippincott-Raven, Philadelphia, 1996: 179–189.

3. Quality of life research within the EORTC—the EORTC QLQ-C30

4. Quality of life measurement: bibliographic study of patient assessed health outcome measures

5. Fayers P, Aaronson N, Bjordal K, Groenvold M, Curran D, Bottomley A. EORTC QLQ-C30 Scoring Manual. 3rd ed., Brussels: European Organization for Research and Treatment of Cancer; 2001.

Cited by 61 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chinese utility weights for the EORTC cancer-specific utility instrument QLU-C10D;Quality of Life Research;2024-09-13

2. Patient-reported outcomes for the phase 3 FURLONG study of furmonertinib versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer;The Lancet Regional Health - Western Pacific;2024-07

3. Cancer-Specific Health Utilities: Evaluation of Core Measurement Properties of the EORTC QLU-C10D in Lung Cancer Patients—Data from Four Multicentre LUX-Lung Trials, Applying Six Country Tariffs;PharmacoEconomics - Open;2024-05-02

4. Experience of cytokine therapy in the treatment of recurrent cervical cancer;Medical Immunology (Russia);2023-06-13

5. Cross-National Vaccine Concerns and Predictors of Vaccine Hesitancy in Not-Fully Vaccinated Individuals: Findings from USA, Canada, Sweden, and Italy;Vaccines;2022-10-01